Диссертация (1144259), страница 24
Текст из файла (страница 24)
-- 2007. -- Jan 1. -- T. 16, № 1. -- C. 61-77.[68] Omi K., Hachiya N. S., Tokunaga K., Kaneko K. siRNA-mediated inhibition ofendogenous Huntington disease gene expression induces an aberrant configuration ofthe ER network in vitro // Biochem Biophys Res Commun. -- 2005. -- Dec 16. -- T. 338,№ 2. -- C. 1229-35.[69] Hilditch-Maguire P., Trettel F., Passani L. A., Auerbach A., Persichetti F.,MacDonald M.
E. Huntingtin: an iron-regulated protein essential for normal nuclear andperinuclear organelles // Hum Mol Genet. -- 2000. -- Nov 22. -- T. 9, № 19. -- C. 278997.[70] Gauthier L. R., Charrin B. C., Borrell-Pages M., Dompierre J. P., Rangone H.,Cordelieres F. P., De Mey J., MacDonald M. E., Lessmann V., Humbert S., Saudou F.Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNFvesicular transport along microtubules // Cell.
-- 2004. -- Jul 9. -- T. 118, № 1. -- C.127-38.[71] Gunawardena S., Her L. S., Brusch R. G., Laymon R. A., Niesman I. R., GordeskyGold B., Sintasath L., Bonini N. M., Goldstein L. S. Disruption of axonal transport byloss of huntingtin or expression of pathogenic polyQ proteins in Drosophila // Neuron. - 2003. -- Sep 25. -- T. 40, № 1. -- C. 25-40.[72] Pal A., Severin F., Lommer B., Shevchenko A., Zerial M. Huntingtin-HAP40complex is a novel Rab5 effector that regulates early endosome motility and is upregulated in Huntington's disease // J Cell Biol. -- 2006.
-- Feb 13. -- T. 172, № 4. -- C.605-18.[73] Tang T. S., Tu H., Chan E. Y., Maximov A., Wang Z., Wellington C. L., HaydenM. R., Bezprozvanny I. Huntingtin and huntingtin-associated protein 1 influenceneuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1 //Neuron. -- 2003. -- Jul 17.
-- T. 39, № 2. -- C. 227-39.[74] Tang T. S., Slow E., Lupu V., Stavrovskaya I. G., Sugimori M., Llinas R., KristalB. S., Hayden M. R., Bezprozvanny I. Disturbed Ca2+ signaling and apoptosis ofmedium spiny neurons in Huntington's disease // Proc Natl Acad Sci U S A. -- 2005. -Feb 15. -- T. 102, № 7. -- C.
2602-7.[75] Bezprozvanny I., Hayden M. R. Deranged neuronal calcium signaling andHuntington disease // Biochem Biophys Res Commun. -- 2004. -- Oct 1. -- T. 322, № 4.-- C. 1310-7.[76] Milakovic T., Johnson G. V. Mitochondrial respiration and ATP production aresignificantly impaired in striatal cells expressing mutant huntingtin // J Biol Chem. -2005. -- Sep 2. -- T. 280, № 35. -- C. 30773-82.- 132 -[77] Panov A. V., Gutekunst C.
A., Leavitt B. R., Hayden M. R., Burke J. R.,Strittmatter W. J., Greenamyre J. T. Early mitochondrial calcium defects inHuntington's disease are a direct effect of polyglutamines // Nat Neurosci. -- 2002. -Aug. -- T. 5, № 8. -- C. 731-6.[78] Cha J. H. Transcriptional dysregulation in Huntington's disease // Trends Neurosci.-- 2000. -- Sep. -- T. 23, № 9. -- C. 387-92.[79] Chan E. Y., Luthi-Carter R., Strand A., Solano S. M., Hanson S.
A., DeJohn M.M., Kooperberg C., Chase K. O., DiFiglia M., Young A. B., Leavitt B. R., Cha J. H.,Aronin N., Hayden M. R., Olson J. M. Increased huntingtin protein length reduces thenumber of polyglutamine-induced gene expression changes in mouse models ofHuntington's disease // Hum Mol Genet.
-- 2002. -- Aug 15. -- T. 11, № 17. -- C. 193951.[80] Dunah A. W., Jeong H., Griffin A., Kim Y. M., Standaert D. G., Hersch S. M.,Mouradian M. M., Young A. B., Tanese N., Krainc D. Sp1 and TAFII130transcriptional activity disrupted in early Huntington's disease // Science. -- 2002. -- Jun21.
-- T. 296, № 5576. -- C. 2238-43.[81] Gusella J. F., MacDonald M. E. Huntington's disease and repeating trinucleotides //N Engl J Med. -- 1994. -- May 19. -- T. 330, № 20. -- C. 1450-1.[82] Tobin A. J., Signer E. R. Huntington's disease: the challenge for cell biologists //Trends Cell Biol. -- 2000. -- Dec. -- T. 10, № 12. -- C. 531-6.[83] Rubinsztein D. C.
Lessons from animal models of Huntington's disease // TrendsGenet. -- 2002. -- Apr. -- T. 18, № 4. -- C. 202-9.[84] Ross C. A. Polyglutamine pathogenesis: Emergence of unifying mechanisms forHuntington's disease and related disorders // Neuron. -- 2002. -- Aug 29. -- T.
35, № 5. - C. 819-822.[85] Li S. H., Li X. J. Huntingtin-protein interactions and the pathogenesis ofHuntington's disease // Trends Genet. -- 2004. -- Mar. -- T. 20, № 3. -- C. 146-54.[86] Bezprozvanny I. Calcium signaling and neurodegenerative diseases // Trends MolMed. -- 2009. -- Mar. -- T. 15, № 3.
-- C. 89-100.[87] Cha J. H. Transcriptional signatures in Huntington's disease // Prog Neurobiol. -2007. -- Nov. -- T. 83, № 4. -- C. 228-48.[88] Silva A., de Almeida A. V., Macedo-Ribeiro S. Polyglutamine expansion diseases:More than simple repeats // J Struct Biol. -- 2018. -- Feb. -- T. 201, № 2. -- C. 139-154.[89] Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C.,Lawton M., Trottier Y., Lehrach H., Davies S. W., Bates G. P.
Exon 1 of the HD genewith an expanded CAG repeat is sufficient to cause a progressive neurologicalphenotype in transgenic mice // Cell. -- 1996. -- Nov 1. -- T. 87, № 3. -- C. 493-506.[90] Menalled L. B., Chesselet M. F. Mouse models of Huntington's disease // TrendsPharmacol Sci. -- 2002. -- Jan. -- T. 23, № 1. -- C. 32-9.[91] Goldberg Y.
P., Nicholson D. W., Rasper D. M., Kalchman M. A., Koide H. B.,Graham R. K., Bromm M., Kazemi-Esfarjani P., Thornberry N. A., Vaillancourt J. P.,Hayden M. R. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, ismodulated by the polyglutamine tract // Nat Genet. -- 1996. -- Aug. -- T. 13, № 4. -- C.442-9.- 133 -[92] Graham R.
K., Deng Y., Slow E. J., Haigh B., Bissada N., Lu G., Pearson J.,Shehadeh J., Bertram L., Murphy Z., Warby S. C., Doty C. N., Roy S., Wellington C.L., Leavitt B. R., Raymond L. A., Nicholson D. W., Hayden M. R. Cleavage at thecaspase-6 site is required for neuronal dysfunction and degeneration due to mutanthuntingtin // Cell. -- 2006. -- Jun 16. -- T.
125, № 6. -- C. 1179-91.[93] Wellington C. L., Ellerby L. M., Gutekunst C. A., Rogers D., Warby S., Graham R.K., Loubser O., van Raamsdonk J., Singaraja R., Yang Y. Z., Gafni J., Bredesen D.,Hersch S. M., Leavitt B. R., Roy S., Nicholson D. W., Hayden M. R. Caspase cleavageof mutant huntingtin precedes neurodegeneration in Huntington's disease // J Neurosci. - 2002. -- Sep 15. -- T. 22, № 18. -- C. 7862-72.[94] Guo Q., Bin H., Cheng J., Seefelder M., Engler T., Pfeifer G., Oeckl P., Otto M.,Moser F., Maurer M., Pautsch A., Baumeister W., Fernandez-Busnadiego R., KochanekS. The cryo-electron microscopy structure of huntingtin // Nature.
-- 2018. -- Mar 1. -T. 555, № 7694. -- C. 117-120.[95] Hu J., Matsui M., Gagnon K. T., Schwartz J. C., Gabillet S., Arar K., Wu J.,Bezprozvanny I., Corey D. R. Allele-specific silencing of mutant huntingtin and ataxin3 genes by targeting expanded CAG repeats in mRNAs // Nat Biotechnol.
-- 2009. -May. -- T. 27, № 5. -- C. 478-84.[96] Hu J., Matsui M., Corey D. R. Allele-selective inhibition of mutant huntingtin bypeptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA// Ann N Y Acad Sci. -- 2009. -- Sep. -- T. 1175. -- C. 24-31.[97] Heiser V., Engemann S., Brocker W., Dunkel I., Boeddrich A., Waelter S.,Nordhoff E., Lurz R., Schugardt N., Rautenberg S., Herhaus C., Barnickel G., BottcherH., Lehrach H., Wanker E.
E. Identification of benzothiazoles as potentialpolyglutamine aggregation inhibitors of Huntington's disease by using an automatedfilter retardation assay // Proc Natl Acad Sci U S A. -- 2002. -- Dec 10. -- T. 99 Suppl 4.-- C. 16400-6.[98] Sanchez I., Mahlke C., Yuan J. Pivotal role of oligomerization in expandedpolyglutamine neurodegenerative disorders // Nature. -- 2003. -- Jan 23. -- T. 421, №6921. -- C. 373-9.[99] Zhang X., Smith D. L., Meriin A. B., Engemann S., Russel D. E., Roark M.,Washington S. L., Maxwell M. M., Marsh J.
L., Thompson L. M., Wanker E. E., YoungA. B., Housman D. E., Bates G. P., Sherman M. Y., Kazantsev A. G. A potent smallmolecule inhibits polyglutamine aggregation in Huntington's disease neurons andsuppresses neurodegeneration in vivo // Proc Natl Acad Sci U S A. -- 2005. -- Jan 18. -T. 102, № 3. -- C.
892-7.[100] Wang J., Gines S., MacDonald M. E., Gusella J. F. Reversal of a full-lengthmutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutaminemediated aggregation // BMC Neurosci. -- 2005. -- Jan 13. -- T. 6. -- C. 1.[101] Ko J., Ou S., Patterson P. H. New anti-huntingtin monoclonal antibodies:implications for huntingtin conformation and its binding proteins // Brain Res Bull. -2001.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
